Tigecycline
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Antibiotics | Tigecycline | LD 100mg IV, then 50mg IV Q12H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
586 | 22 | 42 | N/A | 71-89 | 7-9 | N/A | 0 (N/A) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00560
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Meagher A, Ambrose P, Grasela T, Ellis-Grosse E. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clinical infectious diseases (an official publication of the Infectious Diseases Society of America) (2005); 41(Suppl 5), S333-40.